{
    "id": 456,
    "fullName": "BRAF K601E",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "BRAF K601E lies within the activation segment in the kinase domain of the Braf protein (PMID: 15343278). K601E results in increased Braf kinase activity and downstream activation of MEK and ERK in cell culture (PMID: 22798288, PMID: 28783719, PMID: 32059434), and induces cell proliferation and cell viability in culture (PMID: 29533785).",
            "references": [
                {
                    "id": 11238,
                    "pubMedId": 29533785,
                    "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                },
                {
                    "id": 9692,
                    "pubMedId": 28783719,
                    "title": "Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28783719"
                },
                {
                    "id": 3,
                    "pubMedId": 22798288,
                    "title": "BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22798288"
                },
                {
                    "id": 18079,
                    "pubMedId": 32059434,
                    "title": "BRAF Exon 15 Mutations in Papillary Carcinoma and Adjacent Thyroid Parenchyma: A Search for the Early Molecular Events Associated with Tumor Development.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/32059434"
                },
                {
                    "id": 9694,
                    "pubMedId": 15343278,
                    "title": "Switching on kinases: oncogenic activation of BRAF and the PDGFR family.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15343278"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 673,
        "geneSymbol": "BRAF",
        "terms": [
            "BRAF",
            "B-raf",
            "B-RAF1",
            "BRAF1",
            "NS7",
            "RAFB1"
        ]
    },
    "variant": "K601E",
    "createDate": "05/02/2014",
    "updateDate": "03/10/2020",
    "referenceTranscriptCoordinates": {
        "id": 109188,
        "transcript": "NM_004333",
        "gDna": "chr7:g.140753334T>C",
        "cDna": "c.1801A>G",
        "protein": "p.K601E",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 12070,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, a melanoma patient harboring BRAF K601E demonstrated a partial response and a progression free survival of 32 weeks when treated with Mekinist (trametinib) (PMID: 23248257; NCT01037127).",
            "molecularProfile": {
                "id": 655,
                "profileName": "BRAF K601E"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10005,
                    "pubMedId": 23248257,
                    "title": "Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23248257"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12068,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a melanoma patient harboring BRAF K601E demonstrated a 48% reduction in lymphadenopathy when treated with Mekinist (trametinib) and after more than 36 months of treatment showed a complete response (PMID: 28344857).",
            "molecularProfile": {
                "id": 655,
                "profileName": "BRAF K601E"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8660,
                    "pubMedId": 28344857,
                    "title": "Metastatic BRAF K601E-mutated melanoma reaches complete response to MEK inhibitor trametinib administered for over 36\u00a0months.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28344857"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20146,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Zelboraf (vemurafenib) treatment did not result in response in the cohort of 15 non-small cell lung cancer patients with non-V600 BRAF mutations, which included 3 patients harboring BRAF K601E, and enrollment in this cohort was discontinued (PMID: 31959346; NCT02304809).",
            "molecularProfile": {
                "id": 655,
                "profileName": "BRAF K601E"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 17717,
                    "pubMedId": 31959346,
                    "title": "Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31959346"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18492,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with a pancreatic neuroendocrine tumor harboring BRAF K601E demonstrated progressive disease when treated with Mekinist (trametinib) (PMID: 31158244).",
            "molecularProfile": {
                "id": 655,
                "profileName": "BRAF K601E"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1798,
                "name": "pancreatic endocrine carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 16277,
                    "pubMedId": 31158244,
                    "title": "Rare BRAF mutations in pancreatic neuroendocrine tumors may predict response to RAF and MEK inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31158244"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12069,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, no responses were demonstrated among three melanoma patients with non-V600 BRAF mutations, including two patients harboring BRAF K601E, following treatment with Tafinlar (dabrafenib), compared to a confirmed response rate of 50% in patients harboring BRAF V600 mutations (PMID: 22608338).",
            "molecularProfile": {
                "id": 655,
                "profileName": "BRAF K601E"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 467,
                    "pubMedId": 22608338,
                    "title": "Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22608338"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 698,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment of cells expressing BRAF K601E with the BRAF inhibitor, Zelboraf (vemurafenib), decreased activation of MEK and ERK (PMID: 22798288).",
            "molecularProfile": {
                "id": 655,
                "profileName": "BRAF K601E"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 3,
                    "pubMedId": 22798288,
                    "title": "BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22798288"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9408,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zelboraf (vemurafenib) did not inhibit MEK and ERK activation in transformed cells over expressing the constitutively dimerized BRAF K601E (PMID: 26343582).",
            "molecularProfile": {
                "id": 655,
                "profileName": "BRAF K601E"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 7141,
                    "pubMedId": 26343582,
                    "title": "BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343582"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16108,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (MyPathway), Zelboraf (vemurafenib) treatment resulted in an objective response in only 4% (1/23) of patient with advanced solid tumors harboring non-V600 BRAF mutations, 6 of the non-responding patients harbored BRAF K601E (PMID: 29320312; NCT02091141).",
            "molecularProfile": {
                "id": 655,
                "profileName": "BRAF K601E"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 13171,
                    "pubMedId": 29320312,
                    "title": "Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29320312"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 697,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the MEK inhibitor, Mekinist (trametinib) decreased activation of MEK and ERK in cells expressing BRAF K601E in culture (PMID: 22798288).",
            "molecularProfile": {
                "id": 655,
                "profileName": "BRAF K601E"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3,
                    "pubMedId": 22798288,
                    "title": "BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22798288"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18505,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with a pancreatic neuroendocrine tumor harboring BRAF K601E demonstrated progressive disease when treated with a combination of Tafinlar (dabrafenib) and Mekinist (trametinib) (PMID: 31158244).",
            "molecularProfile": {
                "id": 655,
                "profileName": "BRAF K601E"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1798,
                "name": "pancreatic endocrine carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 16277,
                    "pubMedId": 31158244,
                    "title": "Rare BRAF mutations in pancreatic neuroendocrine tumors may predict response to RAF and MEK inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31158244"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7036,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF K601E and MAP2K2 E207K demonstrated decreased sensitivity to Selumetinib (AZD6244) in culture (PMID: 22197931).",
            "molecularProfile": {
                "id": 24367,
                "profileName": "BRAF K601E MAP2K2 E207K"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 429,
                    "pubMedId": 22197931,
                    "title": "Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22197931"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15618,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Braftovi (encorafenib) inhibited growth of a melanoma cell line harboring BRAF K601E, as well as BRAF S363F, in culture (PMID: 29903896).",
            "molecularProfile": {
                "id": 31117,
                "profileName": "BRAF S363F BRAF K601E"
            },
            "therapy": {
                "id": 796,
                "therapyName": "Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13465,
                    "pubMedId": 29903896,
                    "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15625,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Cotellic (cobimetinib) inhibited growth of a melanoma cell line harboring BRAF K601E, as well as BRAF S363F, in culture (PMID: 29903896).",
            "molecularProfile": {
                "id": 31117,
                "profileName": "BRAF S363F BRAF K601E"
            },
            "therapy": {
                "id": 1004,
                "therapyName": "Cobimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13465,
                    "pubMedId": 29903896,
                    "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15617,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Braftovi (encorafenib) to treatment with Mekinist (trametinib) resulted in increased growth inhibition in a melanoma cell line harboring BRAF K601E, as well as BRAF S363F, in culture (PMID: 29903896).",
            "molecularProfile": {
                "id": 31117,
                "profileName": "BRAF S363F BRAF K601E"
            },
            "therapy": {
                "id": 7661,
                "therapyName": "Encorafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13465,
                    "pubMedId": 29903896,
                    "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15626,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mektovi (binimetinib) inhibited growth of a melanoma cell line harboring BRAF K601E, as well as BRAF S363F, in culture (PMID: 29903896).",
            "molecularProfile": {
                "id": 31117,
                "profileName": "BRAF S363F BRAF K601E"
            },
            "therapy": {
                "id": 807,
                "therapyName": "Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13465,
                    "pubMedId": 29903896,
                    "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15619,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Tafinlar (dabrafenib) to treatment with Mekinist (trametinib) resulted in increased growth inhibition in a melanoma cell line harboring BRAF K601E, as well as BRAF S363F, in culture (PMID: 29903896).",
            "molecularProfile": {
                "id": 31117,
                "profileName": "BRAF S363F BRAF K601E"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13465,
                    "pubMedId": 29903896,
                    "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15623,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) inhibited growth of a melanoma cell line harboring BRAF K601E, as well as BRAF S363F, in culture (PMID: 29903896).",
            "molecularProfile": {
                "id": 31117,
                "profileName": "BRAF S363F BRAF K601E"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13465,
                    "pubMedId": 29903896,
                    "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15620,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Zelboraf (vemurafenib) to treatment with Mekinist (trametinib) resulted in increased growth inhibition in a melanoma cell line harboring BRAF K601E, as well as BRAF S363F, in culture (PMID: 29903896).",
            "molecularProfile": {
                "id": 31117,
                "profileName": "BRAF S363F BRAF K601E"
            },
            "therapy": {
                "id": 4234,
                "therapyName": "Trametinib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13465,
                    "pubMedId": 29903896,
                    "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17465,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with metastatic colon cancer harboring BRAF K601E developed progressive disease after 6 weeks of Mektovi (binimetinib) and Vectibix (panitumumab) combination treatment, MAP2K1 V211D was identified as a co-occuring mutation in the biopsy from the new metastasis site (PMID: 31227518).",
            "molecularProfile": {
                "id": 32620,
                "profileName": "BRAF K601E MAP2K1 V211D"
            },
            "therapy": {
                "id": 8513,
                "therapyName": "Binimetinib + Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 15507,
                    "pubMedId": 31227518,
                    "title": "V211D Mutation in MEK1 Causes Resistance to MEK Inhibitors in Colon Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31227518"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17468,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MAP955 inhibited Rsk and Erk phosphorylation, and resulted in 30% tumor regression in patient-derived xenograft (PDX) models of metastatic colon cancer harboring BRAF K601E and MAP2K1 V211D (PMID: 31227518).",
            "molecularProfile": {
                "id": 32620,
                "profileName": "BRAF K601E MAP2K1 V211D"
            },
            "therapy": {
                "id": 8514,
                "therapyName": "MAP855",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15507,
                    "pubMedId": 31227518,
                    "title": "V211D Mutation in MEK1 Causes Resistance to MEK Inhibitors in Colon Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31227518"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17471,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mektovi (binimetinib) did not inhibit Rsk and Erk phosphorylation, and had no effect on tumor growth in patient-derived xenograft (PDX) models of metastatic colon cancer harboring BRAF K601E and MAP2K1 V211D (PMID: 31227518).",
            "molecularProfile": {
                "id": 32620,
                "profileName": "BRAF K601E MAP2K1 V211D"
            },
            "therapy": {
                "id": 807,
                "therapyName": "Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15507,
                    "pubMedId": 31227518,
                    "title": "V211D Mutation in MEK1 Causes Resistance to MEK Inhibitors in Colon Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31227518"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17472,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mektovi (binimetinib) and Erbitux (cetuximab) combination did not inhibit Rsk and Erk phosphorylation, and had no effect on tumor growth in patient-derived xenograft (PDX) models of metastatic colon cancer harboring BRAF K601E and MAP2K1 V211D (PMID: 31227518).",
            "molecularProfile": {
                "id": 32620,
                "profileName": "BRAF K601E MAP2K1 V211D"
            },
            "therapy": {
                "id": 8515,
                "therapyName": "Binimetinib + Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15507,
                    "pubMedId": 31227518,
                    "title": "V211D Mutation in MEK1 Causes Resistance to MEK Inhibitors in Colon Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31227518"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 655,
            "profileName": "BRAF K601E",
            "profileTreatmentApproaches": [
                {
                    "id": 14302,
                    "name": "LY3009120",
                    "profileName": "BRAF K601E"
                },
                {
                    "id": 14301,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF K601E"
                },
                {
                    "id": 14299,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF K601E"
                },
                {
                    "id": 14300,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF K601E"
                }
            ]
        },
        {
            "id": 24367,
            "profileName": "BRAF K601E MAP2K2 E207K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31117,
            "profileName": "BRAF S363F BRAF K601E",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 32620,
            "profileName": "BRAF K601E MAP2K1 V211D",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 109187,
            "transcript": "XM_005250045",
            "gDna": "chr7:g.140753334T>C",
            "cDna": "c.1801A>G",
            "protein": "p.K601E",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 109188,
            "transcript": "NM_004333",
            "gDna": "chr7:g.140753334T>C",
            "cDna": "c.1801A>G",
            "protein": "p.K601E",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}